Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

To see complete record on, please visit this link

Id: NCT04593563

Organisation Name: Maryland Oncology Hematology, PA

Overal Status: Active, not recruiting

Start Date: September 1, 2020

Last Update: October 15, 2021

Lead Sponsor: Maryland Oncology Hematology, PA

Brief Summary: This is a Phase II, single-center, fixed dose, open label trial to explore the safety, tolerability and efficacy of a 25mg dose of psilocybin in cancer patients with MDD. The study population will include adult men and women, 18 years of age or above, with MDD, diagnosed with a malignant neoplasm. MDD is defined as those who meet DSM 5 diagnostic criteria for a single or recurrent episode of MDD without psychotic features. A diagnosis of a malignant neoplasm is defined as having a diagnostic code from C00 to C97 according to the ICD-10.

  • Major Depressive Disorder

Total execution time in seconds: 0.29211020469666